gilham_low_res_horizon

Ian Gilham appointed chairman of the board at Horizon Discovery





pharmafile | January 17, 2014 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development Gilham, Horizon Discovery 

Research tools firm Horizon Discovery has appointed Dr Ian Gilham as chairman of its board of directors.



 

Gilham’s healthcare industry career spans 30 years, he was chief executive of Axis-Shield, the in vitro diagnostics company acquired by Alere in November 2011 for £235 million. 

Prior to joining Axis-Shield, Gilham held international general management, marketing, business development and R&D positions with GSK, Abbott Laboratories, Celltech and Amersham. Gilham is also currently non-executive chairman of Multiplicom.

Darrin Disley, chief exectuive of Horizon, said: “We are delighted that Ian has decided to accept the position of chairman of the board on a permanent basis. As interim chairman he has made an invaluable contribution to the growth and success of the company.”

Related Content

shutterstock_123182704

Horizon and Fulcrum Therapeutics form CRISPR collaboration

Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to …

Horizon forms new cancer advisory board

UK biotech Horizon Discovery has formed a new Scientific Advisory Board (SAB) for its diagnostics …

Latest content